 NEW YORK, April 13, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry conferences in April: April 17-22: 2021 Virtual American Academy of Neurology AAN Annual Meeting. Robert J. 